Involvement of exogenous 3‑deoxyglucosone in β‑cell dysfunction induces impaired glucose regulation

Zhang,Lurong; Zhou,Liang; Song,Xiudao; Liang,Guoqiang; Xu,Zhongrui; Wang,Fei; Huang,Fei; Jiang,Guorong

doi:10.3892/mmr.2017.6856

Involvement of exogenous 3‑deoxyglucosone in β‑cell dysfunction induces impaired glucose regulation

Authors:
- Lurong Zhang
- Liang Zhou
- Xiudao Song
- Guoqiang Liang
- Zhongrui Xu
- Fei Wang
- Fei Huang
- Guorong Jiang
View Affiliations

Affiliations: Suzhou Academy of Wumen Chinese Medicine, Suzhou Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Suzhou, Jiangsu 215003, P.R. China
Published online on: June 27, 2017 https://doi.org/10.3892/mmr.2017.6856
Pages: 2976-2984

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

β‑cell dysfunction is the primary cause of type 2 diabetes mellitus (T2DM). 1,2‑dicarbonyl compounds, such as 3‑deoxyglucosone (3DG) have been reported to increase the risk of T2DM. Abnormal elevation of plasma 3DG may impair β‑cell function and thereby, it is linked to T2DM. Previous findings suggest that exogenous 3DG may serve an important role in the development of pre‑diabetes. In the present study, the authors examine whether exogenous 3DG induces impaired glucose regulation in mice by decreasing β‑cell function involving of accumulation of plasma 3DG. At two weeks following administration of 3DG, fasting blood glucose (FBG) levels, oral glucose tolerance (by a glucose meter) and plasma levels of 3DG (by HPLC) and insulin (by radioimmunoassay) were measured. Glucose‑stimulated insulin secretion in cultured pancreas islets and INS‑1 cells was measured by radioimmunoassay. Western blotting was used to examine the expression of the key molecules of the insulin‑PI3K signaling pathway. 3DG treatment increased FBG and fasting blood insulin levels, reduced oral glucose tolerance in conjunction with decreased ∆Ins30‑0/∆G30‑0. In 3DG‑treated mice, an increase in the plasma 3DG level was observed, which was most likely the mechanism for decreased β‑cell function. This idea was further supported by these results that non‑cytotoxic 3DG concentration obviously decreased glucose‑stimulated insulin secretion in cultured pancreas islets and INS‑1 cells exposure to high glucose (25.5 mM). 3DG decreased the expression of GLUT2 and phosphorylation of IRS‑1, PI3K‑p85 and Akt in high glucose‑induced INS‑1 cells. To the best of the authors' knowledge, the present study is the first to demonstrate that exogenous 3DG induced normal mice to develop IGR, resulting from β‑cell dysfunction. Exogenous 3DG administration increased plasma 3DG levels, which participates in inducing β‑cell dysfunction, at least in part, through impairing IRS‑1/PI3K/GLUT2 signaling.

View Figures

View References

1	Giuseppe D, Muhammad AG and Defronzo RA: What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmaco. 15:2003–2018. 2014. View Article : Google Scholar
2	Abdul-Ghani MA, Tripathy D and DeFronzo RA: Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care. 29:1130–1139. 2006. View Article : Google Scholar : PubMed/NCBI
3	Rhodes CJ, White MF, Leahy JL and Kahn SE: Direct autocrine action of insulin on β-cells: Does it make physiological sense? Diabetes. 62:2157–2163. 2013. View Article : Google Scholar : PubMed/NCBI
4	Leibiger IB, Leibiger B and Berggren PO: Insulin signaling in the pancreatic beta-cell. Annu Rev Nutr. 28:233–251. 2008. View Article : Google Scholar : PubMed/NCBI
5	Kulkarni RN, Brüning JC, Winnay JN, Postic C, Magnuson MA and Kahn CR: Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 96:329–339. 1999. View Article : Google Scholar : PubMed/NCBI
6	Kulkarni RN: Receptors for insulin and insulin-like growth factor-1 and insulin receptor substrate-1 mediate pathways that regulate islet function. Biochem Soc Trans. 30:317–322. 2002. View Article : Google Scholar : PubMed/NCBI
7	Kulkarni RN, Winnay JN, Daniels M, Brüning JC, Flier SN, Hanahan D and Kahn CR: Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest. 104:R69–R75. 1999. View Article : Google Scholar : PubMed/NCBI
8	Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, et al: Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 391:900–904. 1998. View Article : Google Scholar : PubMed/NCBI
9	Rothenberg PL, Willison LD, Simon J and Wolf BA: Glucose-induced insulin receptor tyrosine phosphorylation in insulin-secreting beta-cells. Diabetes. 44:802–809. 1995. View Article : Google Scholar : PubMed/NCBI
10	Aspinwall CA, Qian WJ, Roper MG, Kulkarni RN, Kahn CR and Kennedy RT: Roles of insulin receptor substrate-1, phosphatidylinositol 3-kinase, and release of intracellular Ca²⁺ stores in insulin-stimulated insulin secretion in beta -cells. J Biol Chem. 275:22331–22338. 2000. View Article : Google Scholar : PubMed/NCBI
11	da Silva Xavier G, Varadi A, Ainscow EK and Rutter GA: Regulation of gene expression by glucose in pancreatic beta -cells (MIN6) via insulin secretion and activation of phosphatidylinositol 3′-kinase. J Biol Chem. 275:36269–36277. 2000. View Article : Google Scholar : PubMed/NCBI
12	Maessen DE, Hanssen NM, Scheijen JL, van der Kallen CJ, van Greevenbroek MM, Stehouwer CD and Schalkwijk CG: Post-glucose load plasma α-dicarbonyl concentrations are increased in individuals with impaired glucose metabolism and type 2 diabetes: The CODAM study. Diabetes Care. 38:913–920. 2015. View Article : Google Scholar : PubMed/NCBI
13	Dhar A, Desai KM and Wu L: Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats. Br J Pharmacol. 159:166–175. 2010. View Article : Google Scholar : PubMed/NCBI
14	Riboulet-Chavey A, Pierron A, Durand I, Murdaca J, Giudicelli J and Van Obberghen E: Methylglyoxal impairs the insulin signaling pathways independently of the formation of intracellular reactive oxygen species. Diabetes. 55:1289–1299. 2006. View Article : Google Scholar : PubMed/NCBI
15	Jia X and Wu L: Accumulation of endogenous methylglyoxal impaired insulin signaling in adipose tissue of fructose-fed rats. Mol Cell Biochem. 306:133–139. 2007. View Article : Google Scholar : PubMed/NCBI
16	Fiory F, Lombardi A, Miele C, Giudicelli J, Beguinot F and Van Obberghen E: Methylglyoxal impairs insulin signalling and insulin action on glucose-induced insulin secretion in the pancreatic beta cell line INS-1E. Diabetologia. 54:2941–2952. 2011. View Article : Google Scholar : PubMed/NCBI
17	Eriksson UJ, Wentzel P, Minhas HS and Thornalley PJ: Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. Diabetes. 47:1960–1966. 1998. View Article : Google Scholar : PubMed/NCBI
18	Degen J, Hellwig M and Henle T: 1,2-dicarbonyl compounds in commonly consumed foods. J Agric Food Chem. 60:7071–7079. 2012. View Article : Google Scholar : PubMed/NCBI
19	Okado A, Kawasaki Y, Hasuike Y, Takahashi M, Teshima T, Fujii J and Taniguchi N: Induction of apoptotic cell death by methylglyoxal and 3-deoxyglucosone in macrophage-derived cell lines. Biochem Biophys Res Commun. 225:219–224. 1996. View Article : Google Scholar : PubMed/NCBI
20	Che W, Asahi M, Takahashi M, Kaneto H, Okado A, Higashiyama S and Taniguchi N: Selective induction of heparin-binding epidermal growth factor-like growth factor by methylglyoxal and 3-deoxyglucosone in rat aortic smooth muscle cells. The involvement of reactive oxygen species formation and a possible implication for atherogenesis in diabetes. J Biol Chem. 272:18453–18459. 1997. View Article : Google Scholar : PubMed/NCBI
21	Kalapos MP: Methylglyoxal in living organisms: Chemistry, biochemistry, toxicology and biological implications. Toxicol Lett. 110:145–175. 1999. View Article : Google Scholar : PubMed/NCBI
22	Niwa T: 3-Deoxyglucosone: Metabolism, analysis, biological activity, and clinical implication. J Chromatogr B Biomed Sci Appl. 731:23–36. 1999. View Article : Google Scholar : PubMed/NCBI
23	Sassi-Gaha S, Loughlin DT, Kappler F, Schwartz ML, Su B, Tobia AM and Artlett CM: Two dicarbonyl compounds, 3-deoxyglucosone and methylglyoxal, differentially modulate dermal fibroblasts. Matrix Biol. 29:127–134. 2010. View Article : Google Scholar : PubMed/NCBI
24	Wang Q, Jiang GR and Zhang LR: Effects of 3-deoxyglucosone on blood glucose of normal mice. Chinese J Diabetes. 18:220–222. 2010.
25	Lal S, Kappler F, Walker M, Orchard TJ, Beisswenger PJ, Szwergold BS and Brown TR: Quantitation of 3-deoxyglucosone levels in human plasma. Arch Biochem Biophys. 342:254–260. 1997. View Article : Google Scholar : PubMed/NCBI
26	Hamada Y, Nakamura J, Fujisawa H, Yago H, Nakashima E, Koh N and Hotta N: Effects of glycemic control on plasma 3-deoxyglucosone levels in NIDDM patients. Diabetes Care. 20:1466–1469. 1997. View Article : Google Scholar : PubMed/NCBI
27	Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD and Szwergold BS: alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care. 24:726–732. 2001. View Article : Google Scholar : PubMed/NCBI
28	Jiang G, Zhang L, Ji Q, Wang F, Xu H, Huang F and Wang C: Accumulation of plasma 3-deoxyglucosone impaired glucose regulation in Chinese seniors: Implication for senile diabetes? Diabetes Metab Syndr. 6:140–145. 2012. View Article : Google Scholar : PubMed/NCBI
29	Liang G, Song X, Xu H, Wang F, Zhang L, Zhou L and Jiang G: 3-Deoxyglucosone induced acute glucose intolerance in sprague-dawley rats: Involvement of insulin resistance and impaired β-cell function. Exp Clin Endocrinol Diabetes. 124:431–436. 2016. View Article : Google Scholar : PubMed/NCBI
30	Liang G, Wang F, Song X, Zhang L, Qian Z and Jiang G: 3-Deoxyglucosone induces insulin resistance by impairing insulin signaling in HepG2 cells. Mol Med Rep. 13:4506–4512. 2016.PubMed/NCBI
31	Kahn SE, Cooper ME and Del Prato S: Pathophysiology and treatment of type 2 diabetes: Perspectives on the past, present, and future. Lancet. 383:1068–1083. 2014. View Article : Google Scholar : PubMed/NCBI
32	Schwartz MW, Seeley RJ, Tschöp MH, Woods SC, Morton GJ, Myers MG and D'Alessio D: Cooperation between brain and islet in glucose homeostasis and diabetes. Nature. 503:59–66. 2013. View Article : Google Scholar : PubMed/NCBI
33	Kato H, van Chuyen N, Shinoda T, Sekiya F and Hayase F: Metabolism of 3-deoxyglucosone, an intermediate compound in the Maillard reaction, administered orally or intravenously to rats. Biochim Biophys Acta. 1035:71–76. 1990. View Article : Google Scholar : PubMed/NCBI
34	Tabák AG, Herder C, Rathmann W, Brunner EJ and Kivimäki M: Prediabetes: A high-risk state for diabetes development. Lancet. 379:2279–2290. 2012. View Article : Google Scholar : PubMed/NCBI
35	Hu FB, Van Dam RM and Liu S: Diet and risk of type II diabetes: The role of types of fat and carbohydrate. Diabetologia. 44:805–817. 2001. View Article : Google Scholar : PubMed/NCBI
36	Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M and Witte DR: Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. Lancet. 373:2215–2221. 2009. View Article : Google Scholar : PubMed/NCBI
37	Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA, et al: San Antonio metabolism study: Beta-cell dysfunction and glucose intolerance: Results from the San Antonio metabolism (SAM) study. Diabetologia. 47:31–39. 2004. View Article : Google Scholar : PubMed/NCBI
38	Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J and Laakso M: Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes. 58:1212–1221. 2009. View Article : Google Scholar : PubMed/NCBI
39	Thorens B, Sarkar HK, Kaback HR and Lodish HF: Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells. Cell. 55:281–290. 1988. View Article : Google Scholar : PubMed/NCBI
40	Unger RH: Diabetic hyperglycemia: Link to impaired glucose transport in pancreatic beta cells. Science. 251:1200–1205. 1991. View Article : Google Scholar : PubMed/NCBI
41	Guillam MT, Hümmler E, Schaerer E, Yeh JI, Birnbaum MJ, Beermann F, Schmidt A, Dériaz N and Thorens B: Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet. 17:327–330. 1997. View Article : Google Scholar : PubMed/NCBI
42	Assmann A, Ueki K, Winnay JN, Kadowaki T and Kulkarni RN: Glucose effects on beta-cell growth and survival require activation of insulin receptors and insulin receptor substrate 2. Mol Cell Biol. 29:3219–3228. 2009. View Article : Google Scholar : PubMed/NCBI
43	Kaneto H, Matsuoka TA, Miyatsuka T, Kawamori D, Katakami N, Yamasaki Y and Matsuhisa M: PDX-1 functions as a master factor in the pancreas. Front Biosci. 13:6406–6420. 2008. View Article : Google Scholar : PubMed/NCBI
44	Brissova M, Shiota M, Nicholson WE, Gannon M, Knobel SM, Piston DW, Wright CV and Powers AC: Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem. 13:11225–11232. 2002. View Article : Google Scholar
45	Sakiyama H, Takahashi M, Yamamoto T, Teshima T, Lee SH, Miyamoto Y, Misonou Y and Taniguchi N: The internalization and metabolism of 3-deoxyglucosone in human umbilical vein endothelial cells. J Biochem. 139:245–253. 2006. View Article : Google Scholar : PubMed/NCBI